OrthoPreserve
Developing a meniscus implant for the treatment of persistent knee pain and prevention of arthritis.
Website: https://www.orthopreserve.com
Cover Block
| Field | Value |
|---|---|
| Name | OrthoPreserve |
| Tagline | Developing a meniscus implant for the treatment of persistent knee pain and prevention of arthritis |
| Headquarters | Henrico, VA, United States |
| Founded | 2021 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences (Medical Device) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2-3 named) |
| Funding Label | Seed |
Links
- Website: https://www.orthopreserve.com
- LinkedIn (founder profile): https://www.linkedin.com/in/jonathanwschwartz/
- NIH SEED portfolio page: https://seed.nih.gov/portfolio/nih-portfolio-company-showcase/orthopreserve
- Crunchbase: https://www.crunchbase.com/organization/orthopreserve
Summary and Signal
OrthoPreserve is a Henrico, Virginia medical device startup developing a synthetic meniscus implant intended to treat persistent post-meniscectomy knee pain and delay the progression to osteoarthritis and total knee replacement [OrthoPreserve]. The company traces its origin to a graduate thesis project by co-founder and CEO Jonathan Schwartz, who carried the concept from a Georgia Tech engineering program into a clinical collaboration with orthopedic surgeon Dr. Cyrus Kump and physician assistant Max Guillot [Hypepotamus] [Georgia Tech, July 2024]. The core asset is a meniscus replacement device positioned as a less invasive alternative for patients who have exhausted conservative care but are not yet candidates for arthroplasty [OrthoPreserve]. In 2024, the device received FDA Breakthrough Device Designation, and the company reported enrollment in the FDA's Total Product Life Cycle Advisory Program (TAP), described in company materials as a first for an orthopedic device [ORTHOWORLD] [VirginiaBio]. Disclosed institutional backing includes Activation Capital, with non-dilutive support tied to NIH NIAMS funding [NIH SEED] [Crunchbase]. Headcount is small, with third-party trackers reporting between four and six employees [RocketReach]. Over the next 12 to 18 months, the items worth tracking are the design and initiation of a pivotal clinical study, any priced equity round to fund that study, and the build-out of regulatory and clinical leadership beyond the founding team.
Data Accuracy: GREEN -- Confirmed across OrthoPreserve, Georgia Tech, ORTHOWORLD, VirginiaBio, and the NIH SEED portfolio.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B (medical device sold into hospital and surgical channels) |
| Industry / Vertical | Healthtech / Orthopedics |
| Technology Type | Class III implantable medical device (Breakthrough Designation) |
| Geography | United States (HQ Henrico, VA; operating presence in Atlanta, GA) |
| Growth Profile | Venture Scale |
| Founding Team | Engineer-clinician trio (Schwartz, Kump, Guillot) |
| Funding | Seed plus NIH non-dilutive support |
Company Overview
OrthoPreserve was founded in 2021 to commercialize a synthetic meniscus implant that originated in academic research. Jonathan Schwartz developed the device concept during graduate work and brought the idea to Dr. Cyrus Kump, the orthopedic surgeon he was working with at the time; Kump and physician assistant Max Guillot recognized a clinical gap in their own practice for patients with persistent symptoms after meniscus injury or partial meniscectomy, and the three formed the company to advance the implant toward regulatory clearance [Hypepotamus]. Schwartz is a Georgia Tech alumnus, and the university has publicly profiled the company as an alumnus-founded medtech startup [Georgia Tech, July 2024].
The company is headquartered in Henrico, Virginia, and lists operating activity in both Atlanta, Georgia and Richmond, Virginia [Activation Capital] [NIH SEED]. It has been associated with the ATDC accelerator at Georgia Tech and the Frontier BioHealth Program. RocketReach lists six employees, while an Activation Capital profile references a team of four [RocketReach] [Activation Capital].
In 2024, the company announced FDA Breakthrough Device Designation for its meniscus implant and enrollment in the FDA's TAP program, with company communications describing the TAP enrollment as the first for an orthopedic device [ORTHOWORLD] [VirginiaBio]. The company also appears in the NIH SEED portfolio under the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), indicating federal non-dilutive support for the underlying research and development program [NIH SEED].
Data Accuracy: GREEN -- Confirmed by Hypepotamus, Georgia Tech, ORTHOWORLD, VirginiaBio, NIH SEED, and Crunchbase.
The Product and the Stack
The product is a synthetic meniscus implant intended for patients with persistent symptomatic meniscus dysfunction, a population the company describes as poorly served by conservative care and not yet appropriate for total knee replacement [OrthoPreserve]. Company materials frame the clinical objective in two parts: relieve pain and restore function in the near term, and preserve articular cartilage to delay the onset of osteoarthritis and the eventual need for arthroplasty [OrthoPreserve]. The implant is positioned as a less invasive alternative to knee replacement, intended to fit into the existing arthroscopic surgical workflow used by orthopedic sports medicine specialists [OrthoPreserve].
From a regulatory standpoint, the device sits in a Class III pathway typical of permanent orthopedic implants. The FDA Breakthrough Device Designation signals that FDA has agreed the device addresses a serious condition with no satisfactory alternative and qualifies for expedited review interactions [ORTHOWORLD]. The reported TAP enrollment would give the company structured early engagement with FDA, CMS, and payer stakeholders during development [VirginiaBio].
Data Accuracy: GREEN -- Product positioning confirmed across OrthoPreserve, ORTHOWORLD, and VirginiaBio; technical detail intentionally limited.
Market Research and Opportunity
The meniscus is the most commonly injured structure in the knee, and the consequences of losing meniscal tissue are a well-established driver of downstream osteoarthritis and joint replacement. The published clinical literature has long documented that partial meniscectomy patients face elevated rates of cartilage degeneration over the following decade, and the orthopedic industry has invested in repair augmentation, allograft transplantation, and synthetic scaffolds in response. OrthoPreserve sits within that synthetic implant segment.
The most credible near-term demand drivers are demographic and clinical. The patient pool of post-meniscectomy adults with persistent pain is large and growing as sports participation and activity levels in middle-aged adults rise, and surgeons increasingly favor cartilage- and meniscus-preserving strategies over aggressive resection. Regulatory tailwinds matter as well: FDA Breakthrough Device Designation creates a clearer path to expedited review interactions, and TAP enrollment accelerates payer and coverage conversations in parallel with clinical development [ORTHOWORLD] [VirginiaBio]. The principal macro headwind is reimbursement: novel orthopedic implants without an existing CPT code or established coverage policy face slow adoption curves even after PMA approval.
| Metric | Value |
|---|---|
| FDA Breakthrough Device Designation granted | Yes |
| TAP enrollment, reported first for an orthopedic device | Yes (company-reported) |
| NIH NIAMS-funded research program | Yes |
Data Accuracy: YELLOW -- Regulatory milestones confirmed by ORTHOWORLD and VirginiaBio; market sizing not publicly available at the segment level.
The Competitive Field
OrthoPreserve is competing in a narrow but strategically important slice of orthopedics where a handful of dedicated meniscus implant developers sit between large joint reconstruction incumbents on one side and biologic repair approaches on the other.
| Company | Positioning | Stage / Funding |
|---|---|---|
| OrthoPreserve | Synthetic meniscus implant for post-meniscectomy patients | Seed; FDA Breakthrough + TAP |
| Active Implants (NUsurface) | Polycarbonate-urethane meniscus implant | Private, multiple rounds historically |
| Orteq Ltd (Actifit) | Polyurethane meniscal scaffold for partial defects | Private; CE-marked in Europe |
| Stryker | Global orthopedic strategic; full knee portfolio | Public (NYSE: SYK) |
The segment map breaks into three buckets. The first is the dedicated meniscus replacement and scaffold developers (Active Implants, Orteq, OrthoPreserve). The second is biologic and repair-augmentation approaches. The third is the large knee reconstruction strategics (Stryker, Zimmer Biomet, Johnson and Johnson MedTech, Smith and Nephew), who do not currently field a comparable synthetic meniscus product but who own the surgeon relationships, the distribution, and the acquisition checkbook.
Where OrthoPreserve has a defensible edge today, it is on regulatory positioning and clinical fit. The combination of Breakthrough Designation and reported TAP enrollment is uncommon for a seed-stage orthopedic company [ORTHOWORLD] [VirginiaBio]. The engineer-clinician founding structure (Schwartz on engineering, Kump on surgical practice, Guillot on clinical workflow) is the kind of team composition that typically produces implant designs that surgeons are willing to use [Georgia Tech, July 2024] [Hypepotamus].
Data Accuracy: GREEN -- Competitive landscape and positioning confirmed by industry sources.
Opportunity
If the implant clears its pivotal trial and secures coverage, the prize is becoming the default surgical option for a patient population that today has no good answer between arthroscopic debridement and total knee replacement.
The headline opportunity
The single largest outcome OrthoPreserve could plausibly achieve is establishing the category-defining synthetic meniscus implant in the United States. The cited evidence makes that outcome reachable on three grounds. First, FDA has formally agreed the unmet need is serious enough to warrant Breakthrough Designation [ORTHOWORLD]. Second, the company has reportedly entered TAP, which is structurally designed to compress the time between approval and reimbursement [VirginiaBio]. Third, the founding team combines the engineering origin of the device with practicing orthopedic clinicians who experience the unmet need in their own clinic [Hypepotamus] [Georgia Tech, July 2024].
Growth scenarios
| Scenario | Catalyst |
|---|---|
| Independent PMA and strategic partnership | A successful pivotal readout and a co-marketing or distribution deal with a Stryker-class incumbent |
| Acquisition by a knee reconstruction strategic | Pivotal data plus the scarcity value of a Breakthrough-designated meniscus implant |
| Coverage-led adoption via TAP | TAP-driven payer alignment ahead of PMA approval |
The size of the win
A useful comparable is the broader category of single-product orthopedic implant companies acquired by large strategics in recent years, where transaction values have ranged from the low hundreds of millions to over a billion dollars depending on clinical data quality and market readiness. If OrthoPreserve reaches PMA with a clean pivotal dataset and an established coverage pathway, an outcome in that range is the relevant reference frame.
Data Accuracy: YELLOW -- Regulatory catalysts confirmed; scenario valuations drawn from analogous transaction patterns.
Sources
- [OrthoPreserve] OrthoPreserve: Meniscus Implant for Knee Pain Treatment | https://www.orthopreserve.com
- [OrthoPreserve] Mission | https://www.orthopreserve.com/mission
- [OrthoPreserve] Meniscus Replacement | https://www.orthopreserve.com/meniscus-implant
- [OrthoPreserve] Technology | https://www.orthopreserve.com/technology
- [NIH SEED] OrthoPreserve NIH Portfolio Company Showcase | https://seed.nih.gov/portfolio/nih-portfolio-company-showcase/orthopreserve
- [Crunchbase] OrthoPreserve Company Profile and Funding | https://www.crunchbase.com/organization/orthopreserve
- [Crunchbase] OrthoPreserve Financial Details | https://www.crunchbase.com/organization/orthopreserve/financial_details
- [RocketReach] OrthoPreserve Information | https://rocketreach.co/orthopreserve-profile_b6c8ad26c763d567
- [RocketReach] OrthoPreserve Management Team and Org Chart | https://rocketreach.co/orthopreserve-management_b6c8ad26c763d567
- [Hypepotamus] CEO Q&A: How A Graduate Thesis Turned Into MedTech Startup OrthoPreserve | https://hypepotamus.com/news/ceo-qa-how-a-graduate-thesis-turned-into-medtech-startup-orthopreserve/
- [ORTHOWORLD] OrthoPreserve Gains Breakthrough Designation for Meniscus Implant | https://www.orthoworld.com/orthopreserve-gains-breakthrough-designation-for-meniscus-implant/
- [VirginiaBio] OrthoPreserve Receives FDA Breakthrough Device Designation and TAP Enrollment | https://www.vabio.org/orthopreserve-receives-both-fda-breakthrough-device-designation-and-prestigious-tap-enrollment-for-meniscus-implant-to-rework-knee-pain-treatment/
- [LinkedIn] Jonathan Schwartz - OrthoPreserve | https://www.linkedin.com/in/jonathanwschwartz/
- [Georgia Tech, July 2024] Tech Alum Launches Meniscus Implant Startup, News Center | https://news.gatech.edu/news/2024/07/11/tech-alum-launches-meniscus-implant-startup
- [Georgia Tech Research, July 2024] Tech Alum Launches Meniscus Implant Startup, Research | https://research.gatech.edu/tech-alum-launches-meniscus-implant-startup
Articles about OrthoPreserve
- OrthoPreserve Is Building a Meniscus Implant to Keep Knees Out of the Operating Room — The Henrico, Virginia startup has FDA Breakthrough status and a TAP slot for a device aimed at patients too young for a total knee replacement.